Illumina (ILMN)
(Delayed Data from NSDQ)
$153.49 USD
+3.73 (2.49%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $150.00 -3.49 (-2.27%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$153.49 USD
+3.73 (2.49%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $150.00 -3.49 (-2.27%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Zacks News
Neogen Gains on Strong Genomic Arm Amid Stiff Competition
by Zacks Equity Research
Neogen's (NEOG) genomic business shows steady growth on acquisitions in Australia and Brazil. Stiff rivalry a cause of concern.
Illumina (ILMN) Is Up 1.45% in One Week: What You Should Know
by Zacks Equity Research
Does Illumina (ILMN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here is Why Growth Investors Should Buy Illumina (ILMN) Now
by Zacks Equity Research
Illumina (ILMN) could produce exceptional returns because of its solid growth attributes.
Can Medical Devices Strength Drive Abbott (ABT) Q4 Earnings?
by Zacks Equity Research
Abbott (ABT) Q4 results likely to show continued growth in Medical Devices business.
Here's Why You Should Buy Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
On the success of the Elevate 2020 program, along with augmenting reimbursements for tests, Myriad Genetics (MYGN) seems to be well-positioned to deliver strong financial results in fiscal 2019.
Henry Schein Animal Health Spin-Off Approaches, Cost Mounts
by Zacks Equity Research
Henry Schein's (HSIC) animal health spin-off will help it boost growth opportunities in dental space to deliver quality clinical care plus advanced wellness and prevention.
Illumina (ILMN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Illumina (ILMN) closed at $305.63 in the latest trading session, marking a +0.05% move from the prior day.
The Zacks Analyst Blog Highlights: Intuitive Surgical, Illumina, HCA, Elanco Animal and Humana
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intuitive Surgical, Illumina, HCA, Elanco Animal and Humana
Why You Should Consider Buying Omnicell (OMCL) Stock Now
by Zacks Equity Research
Omnicell (OMCL) is pulling out all the stops to strengthen the medication adherence segment.
5 Great Medical Stocks to Buy Ahead of Q4 Earnings
by Swarup Gupta
A Reuters review of Wall Street Research firms reveals that health care is the most favored of the S&P 500's 11 major sectors.
QIAGEN QFT-Plus Ok'd in Canada, Test Customer Base Expands
by Zacks Equity Research
QIAGEN (QGEN) progresses with plans to widen customer base for QuantiFERON-TB Gold Plus test.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
Illumina's (ILMN) product launches continue to contribute to the top line. The company's recent broadening of genotyping sequencing line buoys optimism.
Has Illumina (ILMN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ILMN) Outperforming Other Medical Stocks This Year?
Why Illumina (ILMN) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Illumina (ILMN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Illumina (ILMN) closed the most recent trading day at $307.89, moving +1.72% from the previous trading session.
3 Medical Stocks Likely to Emulate Illumina's Success in 2019
by Urmimala Biswas
Illumina's (ILMN) gains are indeed staggering. But is it the sole star in the firmament setting benchmarks for others to try and emulate?
Here's Why You Should Buy Express Scripts (ESRX) Stock Now
by Zacks Equity Research
Strong demand for Express Scripts' (ESRX) solutions like SafeGuardRx, 90-day supply for chronic medications, exclusive Accredo Specialty Pharmacy and advanced opioid solutions buoy optimism.
AMAG to Acquire Ciraparantag Maker Perosphere Pharmaceuticals
by Zacks Equity Research
AMAG inks a deal to buy Perosphere Pharmaceuticals, which will add the latter's investigational candidate, ciraparantag, to its portfolio.
Here's Why You Should Hold Allscripts Stock in Your Portfolio
by Zacks Equity Research
Allscripts (MDRX) has been winning contracts in the Sunrise EHR platform; competition stiff.
New Strong Buy Stocks for December 14th
by Nitish Marwah
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ILMN) Outperforming Other Medical Stocks This Year?
BD Gets Enterprise Level Cybersecurity Assessment From UL
by Zacks Equity Research
BD (BDX) receives UL CAP for BD FACSLyric flow cytometer with BD FACSuite Clinical software.
Here's Why Investors Should Hold Masimo (MASI) Stock Now
by Zacks Equity Research
Masimo (MASI) gains from solid prospects in the SET Pulse Oximeter platform. However, cutthroat competition in the MedTech space is likely to hurt the stock.
Illumina (ILMN) Takes Part in NIH Program With Genotype Launch
by Zacks Equity Research
The new Infinium Global Diversity Array of Illumina (ILMN) will process up to 1 million cost-free samples to the three genome centers.